Premium
Induction of podoplanin by transforming growth factor‐β in human fibrosarcoma
Author(s) -
Suzuki Hiroyuki,
Kato Yukinari,
Kaneko Mika Kato,
Okita Yukari,
Narimatsu Hisashi,
Kato Mitsuyasu
Publication year - 2008
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2007.12.028
Subject(s) - podoplanin , ht1080 , fibrosarcoma , cancer research , transforming growth factor , transforming growth factor beta , carcinogenesis , malignancy , chemistry , biology , cancer , microbiology and biotechnology , medicine , tumor cells , immunology , lymphatic system , genetics
Podoplanin/aggrus is increased in tumors and its expression was associated with tumor malignancy. Podoplanin on cancer cells serves as a platelet‐aggregating factor, which is associated with the metastatic potential. However, regulators of podoplanin remain to be determined. Transforming growth factor‐β (TGF‐β) regulates many physiological events, including tumorigenesis. Here, we found that TGF‐β induced podoplanin in human fibrosarcoma HT1080 cells and enhanced the platelet‐aggregating‐ability of HT1080. TGF‐β type I receptor inhibitor (SB431542) and short hairpin RNAs for Smad4 inhibited the podoplanin induction by TGF‐β. These results suggest that TGF‐β is a physiological regulator of podoplanin in tumor cells.